Living Cell Technologies Ltd, which has developed a way to transplant working insulin-producing cells from pigs to humans, reviewed the cases of eight people who underwent the procedure from 2007 in Russia.

We are encouraged that we have confirmed (transplant treatment) may be safely administered up to three times and that we have seen proof of continuing efficacy.

The New Zealand-based company which is developing what is effectively a cure for Type 1 diabetes has reported a successful safety and tolerance review.

The company is undertaking further human trials in New Zealand, using higher doses of insulin-producing pig cells, in a bid to find an optimal level for a once-off transplant.

We are contented that our treatment has shown so far to be safe and well tolerated, Professor Bob Elliot said, medical director and founder of LCT.

Six had improved control over their diabetes and significantly, two were able to temporarily stop insulin injections altogether for four and 32 weeks respectively.

Despite of this, none of the patients showed signs of any pig-related disease.

We're in the business now of dose seeking, of getting the dose right, Prof Elliott said.